Baidu
map

Cancer Cell:科学家掌握了癌症的“进化史”,攻克癌症不再是难题!

2017-08-15 Heather_z727 来宝网

能够预测肿瘤细胞对药物的耐药性或敏感性是癌症精确治疗的关键成功因素。但是,这样的预测是很难做到的,因为肿瘤的基因改变随着时间的推移而动态变化,而且通常是相互依赖的,这是一种缺乏了解的模式。

【掌握癌症的进化,个性化治疗癌症】能够预测肿瘤细胞对药物的耐药性或敏感性是癌症精确治疗的关键成功因素。但是,这样的预测是很难做到的,因为肿瘤的基因改变随着时间的推移而动态变化,而且通常是相互依赖的,这是一种缺乏了解的模式。

瑞士洛桑大学生物信息学研究所最近的一项研究为预测癌症的耐药性提供了一个很有前景的框架,他们预测了大约500种已知肿瘤改变,以及它们对超过200种常见癌症药物的反应。发表在《癌症细胞》上的研究表明,虽然基因改造的某些共同作用会使肿瘤细胞对特定药物产生耐药性,但也会使它们对其他意想不到的药物敏感。

癌症是一种不断变化的疾病,它通过出现和选择新的基因改变而进化。为了将特定的药物与这种改变相匹配,并预测它们的反应,就需要了解变化是如何相互依存,并在肿瘤中共同发生的。

研究人员表示:“如果你把基因改造视为食品,那么癌细胞就不是一堆被困在冰箱里的产品,而是精心设计的晚餐菜单,在这些菜单中,菜肴的组合和味道都是匹配的。”

在此次研究中,研究人员能够研究肿瘤的变化是如何相互依赖的,以及这些依赖性如何决定癌症的进化。他们提供了一份关于500个已知肿瘤改变和一个强有力的理论框架的相关性图,以预测这种改变的共同发生,以及他们对超过200种常见癌症药物的预期反应。

研究小组发现,基因组改变的某些依赖性可能会使肿瘤细胞对特定药物产生耐药性,而同时也是“阿喀琉斯之踵”,让它们对其他意想不到的药物过敏。例如,通过分析1000个细胞株的数据,研究小组可以预测,当基因突变和RNF43的突变发生时,细胞对vx - 680(一种抑制细胞增殖的极光激酶的药物)变得敏感。

因此,作者提出了一种新的关于癌症进化的思考方式:“与疾病相关的基因改变并不是随机选择的,而是完全基于它们的单一效应,但结合进化来最大化它们的协同作用。”为了证明他们的发现,研究小组使用了来自癌症基因组图谱的最全面分子数据集,其中包括来自23种肿瘤类型的6,456个人类肿瘤样本。这类癌基因依赖性图谱是改善个性化治疗方法设计的关键第一步,可以作为功能和临床前研究的参考。

原始出处:Marco Mina, Franck Raynaud, Daniele Tavernari, et al.  Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies. Cancer Cell, 2017.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1960380, encodeId=d214196038079, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 26 03:20:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870120, encodeId=a55718e01209e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Mar 31 01:20:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780729, encodeId=a0ac1e8072973, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Mar 29 21:20:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233929, encodeId=616f23392940, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 16 00:13:33 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233825, encodeId=f6d9233825e2, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Aug 15 15:14:54 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233798, encodeId=0bca233e982f, content=世界难题,攻克癌症指日可待。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Aug 15 11:13:04 CST 2017, time=2017-08-15, status=1, ipAttribution=)]
    2018-05-26 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1960380, encodeId=d214196038079, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 26 03:20:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870120, encodeId=a55718e01209e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Mar 31 01:20:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780729, encodeId=a0ac1e8072973, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Mar 29 21:20:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233929, encodeId=616f23392940, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 16 00:13:33 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233825, encodeId=f6d9233825e2, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Aug 15 15:14:54 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233798, encodeId=0bca233e982f, content=世界难题,攻克癌症指日可待。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Aug 15 11:13:04 CST 2017, time=2017-08-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1960380, encodeId=d214196038079, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 26 03:20:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870120, encodeId=a55718e01209e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Mar 31 01:20:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780729, encodeId=a0ac1e8072973, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Mar 29 21:20:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233929, encodeId=616f23392940, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 16 00:13:33 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233825, encodeId=f6d9233825e2, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Aug 15 15:14:54 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233798, encodeId=0bca233e982f, content=世界难题,攻克癌症指日可待。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Aug 15 11:13:04 CST 2017, time=2017-08-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1960380, encodeId=d214196038079, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 26 03:20:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870120, encodeId=a55718e01209e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Mar 31 01:20:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780729, encodeId=a0ac1e8072973, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Mar 29 21:20:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233929, encodeId=616f23392940, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 16 00:13:33 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233825, encodeId=f6d9233825e2, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Aug 15 15:14:54 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233798, encodeId=0bca233e982f, content=世界难题,攻克癌症指日可待。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Aug 15 11:13:04 CST 2017, time=2017-08-15, status=1, ipAttribution=)]
    2017-08-16 luominglian113

    学习了,谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1960380, encodeId=d214196038079, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 26 03:20:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870120, encodeId=a55718e01209e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Mar 31 01:20:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780729, encodeId=a0ac1e8072973, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Mar 29 21:20:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233929, encodeId=616f23392940, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 16 00:13:33 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233825, encodeId=f6d9233825e2, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Aug 15 15:14:54 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233798, encodeId=0bca233e982f, content=世界难题,攻克癌症指日可待。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Aug 15 11:13:04 CST 2017, time=2017-08-15, status=1, ipAttribution=)]
    2017-08-15 三生有幸9135

    学习一下谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1960380, encodeId=d214196038079, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 26 03:20:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870120, encodeId=a55718e01209e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Mar 31 01:20:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780729, encodeId=a0ac1e8072973, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Mar 29 21:20:00 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233929, encodeId=616f23392940, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 16 00:13:33 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233825, encodeId=f6d9233825e2, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Aug 15 15:14:54 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233798, encodeId=0bca233e982f, content=世界难题,攻克癌症指日可待。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Aug 15 11:13:04 CST 2017, time=2017-08-15, status=1, ipAttribution=)]
    2017-08-15 1e0f8808m18(暂无匿称)

    世界难题,攻克癌症指日可待。

    0

相关资讯

JAMA Oncol.:BRCA1/2基因突变状态能否预测三阴乳腺癌新辅助化疗效果?

GeparSixto研究结果显示,含卡铂的联合方案(蒽环类、紫杉等)对三阴乳腺癌患者改善了无疾病生存(DFS)(p=0.56,p=0.372), 同时将病理完全缓解率(pCR)转化为DFS优势。BRCA1和BRCA2突变状态是否会影响治疗结果?通过二次数据分析,结果显示,对于没有BRCA1和BRCA2基因突变的患者,新辅助化疗方案中加入卡铂可以显着提高病理完全缓解率及无疾病生存,但是对于BRCA1

J Clin Oncol:儿童低级别胶质瘤中BRAF V600E突变对治疗和预后的意义

儿童低级别胶质瘤中,BRAF V600E的生物学意义和临床意义尚未完全明确。本文即对这一问题进行了研究。

JAMA Oncology:三阴性乳腺癌基因突变状态、病理完全缓解与无病生存

GeparSixto临床试验结果表明在蒽环类药物、紫杉烷以及贝伐单抗组成的治疗方案外额外增加卡铂辅助治疗可以三阴性乳腺癌患者病理完全缓解(pCR)率。但是BRAC1和BRAC2基因突变状态是否会影响治疗结果尚不明确。JAMA Oncology近期发表了一篇文章,研究三阴性乳腺癌患者BRAC1和BRAC2基因突变状态是否影响治疗反应。

J Dent Res:NOD2基因缺陷与侵袭性牙周炎的联系

侵袭性牙周炎(AgP)会导致牙槽骨的快速破坏以及牙齿的早期缺失,然而其发病机制还不完全清楚。为了探索AgP的遗传风险因素,研究者进行了全基因组单核苷酸多态性的基因分型研究,以此来确定血缘同一的基因图谱以及鉴别32个不同的后补基因位点,随后分析2个家族谱系AgP患者的整个外显子序列,包含一个家庭中的3个病例和1个对照以及另一个家庭中同胞兄弟的2个病例。

“75%的DNA是垃圾”全新争议性研究再引热议

结合基因突变率和史前生殖率,Graur的团队计算出人体内只有8%~14%的DNA可能起作用。

我国发现国际首例新等位基因突变A3亚型血型

近日,江苏省血液中心输血研究室陈青研究员带领的课题组,在国际上首次发现并报道了ABO血型系统中,由于新等位基因突变导致的新的A3亚型的等位基因,这一新发现已被国际基因库收录并公布(序列号为KX870187)。

Baidu
map
Baidu
map
Baidu
map